Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print]. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW et al. Haematologica. 2017…
Gastric submucosal haematoma caused by an amyloidoma in the setting of multiple myeloma. Pak SC et al. Arab J Gastroenterol. 2017 Dec 14. pii: S1687-1979(17)30116-8. doi: 10.1016/j.ajg.2017.12.002. [Epub ahead of print]. A case of Multiple Myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Vignon M et al. Joint Bone Spine. 2017 Dec 9. pii: S1297-319X(17)30203-8. doi: 10.1016/j.jbspin.2017.11.013. [Epub ahead of print]. Systolic dysfunction associated…
The National Institute of Health and Care Excellence (NICE) has recommended the use of ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 2 or 3 prior treatments. This…
New agents in the Treatment of Myeloma Bone Disease.
Ring ES et al. Calcif Tissue Int. 2017 Nov 2. doi: 10.1007/s00223-017-0351-7. [Epub ahead of print].
Ciprofloxacin versus Levofloxacin for prophylaxis during Hematopoietic Stem Cell Transplantation.
Copeland V et al. Clin Transplant. 2017 Oct 28. doi: 10.1111/ctr.13145. [Epub ahead of print].
Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print]. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi:…
Final analysis of survival outcomes in the randomized phase 3 FIRST trial. Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print]. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print]. An overview of the…
Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. Maki H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.8886-17. [Epub ahead of print]. Severe Hypoglycemia Caused by Lenalidomide. Przybylski DJ et al. Pharmacotherapy. 2017 Nov 20. doi: 10.1002/phar.2061. [Epub ahead of print]. Cardiovascular complications of multiple myeloma in the elderly. Mathur P et al. Expert Rev Cardiovasc Ther. 2017 Nov…
This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.